What is hC Bioscience?
Founded in 2021, hC Bioscience operates at the intersection of synthetic biology and clinical medicine. The company is dedicated to the development of tRNA therapies, a novel modality designed to correct protein synthesis errors at the source. By leveraging its unique platform, the firm is positioned to tackle a broad spectrum of genetic disorders that have historically been considered undruggable. Its strategic location in the Cambridge biotech hub provides proximity to top-tier research institutions and a robust talent pool, facilitating rapid iteration of its therapeutic pipeline.
How much funding has hC Bioscience raised?
hC Bioscience has raised a total of $36M across 2 funding rounds:
Unspecified
$12M
Series A
$24M
Unspecified (2021): $12M, investors not publicly disclosed
Series A (2022): $24M led by Takeda Ventures, 8VC, and ARCH Venture Partners
Key Investors in hC Bioscience
ARCH Venture Partners
ARCH Venture Partners is a leading early-stage venture capital firm that creates and invests in life sciences and advanced technology companies, often co-founding startups with scientists and entrepreneurs to commercialize innovations from universities, corporate R&D groups, and national laboratories.
Takeda Ventures
The corporate venture arm of Takeda Pharmaceutical, focusing on strategic investments in innovative biotechnology companies that align with the parent company's therapeutic areas of interest.
8VC
A technology-focused venture capital firm that partners with entrepreneurs to build companies that solve fundamental problems in large industries, including healthcare and life sciences.
What's next for hC Bioscience?
The recent capital injection is earmarked for the acceleration of preclinical development and the expansion of the company's research infrastructure. As hC Bioscience transitions from its initial foundational phase into a more mature scaling stage, the focus will shift toward validating its lead candidates in vivo and establishing strategic partnerships to broaden its therapeutic reach. Investors are closely monitoring the firm's ability to translate its tRNA platform into clinical-grade assets, a milestone that would represent a significant breakthrough in the treatment of protein-dysfunction diseases. The company's trajectory suggests a move toward Series B or beyond as it seeks to solidify its leadership in the emerging field of tRNA-based medicine.
See full hC Bioscience company page
